Synthetic Biologics Company Profile (NYSEMKT:SYN)

About Synthetic Biologics (NYSEMKT:SYN)

Synthetic Biologics logoSynthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:SYN
  • CUSIP: N/A
  • Web: www.syntheticbiologics.com
Capitalization:
  • Market Cap: $114.78 million
  • Outstanding Shares: 128,247,000
Average Prices:
  • 50 Day Moving Avg: $0.88
  • 200 Day Moving Avg: $0.64
  • 52 Week Range: $0.41 - $1.63
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.58
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.04 per share
  • Price / Book: 23.55
Profitability:
  • EBITDA: ($33,770,000.00)
  • Return on Equity: -461.33%
  • Return on Assets: -103.45%
Misc:
  • Average Volume: 1.44 million shs.
  • Beta: 1.39
 

Frequently Asked Questions for Synthetic Biologics (NYSEMKT:SYN)

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "SYN."

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics Inc (NYSEMKT:SYN) announced its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.06) by $0.03. View Synthetic Biologics' Earnings History.

Where is Synthetic Biologics' stock going? Where will Synthetic Biologics' stock price be in 2017?

4 equities research analysts have issued twelve-month price objectives for Synthetic Biologics' stock. Their forecasts range from $5.00 to $6.00. On average, they anticipate Synthetic Biologics' share price to reach $5.50 in the next year. View Analyst Ratings for Synthetic Biologics.

Who are some of Synthetic Biologics' key competitors?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the folowing people:

  • Jeffrey Lucero Riley, President, Chief Executive Officer, Director
  • Steven A. Shallcross, Chief Financial Officer, Treasurer, Secretary
  • Jeffrey J. Kraws, Non-Executive Independent Chairman of the Board
  • Scott L. Tarriff, Independent Director
  • Jeffrey Alan Wolf J.D., Independent Director

How do I buy Synthetic Biologics stock?

Shares of Synthetic Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of Synthetic Biologics stock can currently be purchased for approximately $0.90.


MarketBeat Community Rating for Synthetic Biologics (NYSEMKT SYN)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Synthetic Biologics (NYSEMKT:SYN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $5.50
Consensus Price Target History for Synthetic Biologics (NYSEMKT:SYN)
Price Target History for Synthetic Biologics (NYSEMKT:SYN)
Analysts' Ratings History for Synthetic Biologics (NYSEMKT:SYN)
Show:
DateFirmActionRatingPrice TargetDetails
5/22/2017William BlairReiterated RatingOutperform$5.00View Rating Details
1/14/2017FBR & CoReiterated RatingOverweight$6.00View Rating Details
11/25/2016LaurentianDowngradeBuy -> Speculative BuyView Rating Details
11/25/2016Laurentian Bank of CanadaDowngradeBuy -> Speculative BuyView Rating Details
8/31/2016Griffin SecuritiesSet Price TargetBuy$9.00 -> $5.80View Rating Details
8/25/2016BTIG ResearchInitiated CoverageBuy$5.00View Rating Details
2/5/2016Royal Bank Of CanadaReiterated RatingOutperform$8.00View Rating Details
1/4/2016Telsey Advisory GroupInitiated CoverageOutperformView Rating Details
10/29/2015MackieInitiated CoverageSpeculative BuyC$2.00View Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Synthetic Biologics (NYSEMKT:SYN)
Earnings by Quarter for Synthetic Biologics (NYSEMKT:SYN)
Earnings History by Quarter for Synthetic Biologics (NYSEMKT SYN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/3/2017Q2 2017($0.06)($0.03)ViewListenView Earnings Details
5/4/2017Q1 2017($0.07)($0.02)ViewListenView Earnings Details
3/2/2017Q4 2016($0.08)($0.02)ViewListenView Earnings Details
11/1/2016Q316($0.10)($0.09)ViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.12)ViewN/AView Earnings Details
3/10/2016Q415($0.12)($0.12)ViewListenView Earnings Details
11/5/2015Q315($0.12)($0.12)ViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.19)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.11)ViewListenView Earnings Details
3/16/2015($0.06)($0.09)ViewN/AView Earnings Details
11/14/2014Q314($0.05)($0.08)ViewN/AView Earnings Details
8/14/2014($0.06)($0.08)ViewN/AView Earnings Details
5/15/2014Q1 14($0.08)($0.07)ViewN/AView Earnings Details
3/31/2014($0.06)($0.09)ViewN/AView Earnings Details
11/14/2013Q3($0.06)($0.08)ViewListenView Earnings Details
8/14/2013Q2 2013($0.06)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Synthetic Biologics (NYSEMKT:SYN)
Current Year EPS Consensus Estimate: $-0.170 EPS
Next Year EPS Consensus Estimate: $-0.250 EPS

Dividends

Dividend History for Synthetic Biologics (NYSEMKT:SYN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Synthetic Biologics (NYSEMKT:SYN)
Insider Trades by Quarter for Synthetic Biologics (NYSEMKT:SYN)
Institutional Ownership by Quarter for Synthetic Biologics (NYSEMKT:SYN)
Insider Trades by Quarter for Synthetic Biologics (NYSEMKT:SYN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Brendan CannonDirectorBuy5,000$0.39$1,925.00
11/30/2015Christoper MartinDirectorBuy80,000$0.40$32,000.00
11/27/2015Bartley Vaden HeathDirectorBuy35,000$0.28$9,800.00
9/2/2015Randal J KirkMajor ShareholderBuy937,500$3.20$3,000,000.00View SEC Filing  
5/22/2014Charles Evan BallantyneCFOBuy10,000$1.35$13,500.00View SEC Filing  
4/29/2014Steve H KanzerDirectorSell263,112$2.90$763,024.80View SEC Filing  
12/17/2013Randal J KirkMajor ShareholderBuy2,500,000$1.00$2,500,000.00View SEC Filing  
1/7/2013Jeffrey Scott RileyCEOBuy2,900$0.17$493.00View SEC Filing  
1/3/2013Jeffrey Scott RileyCEOBuy2,000$1.71$3,420.00View SEC Filing  
10/29/2012Randal J KirkMajor ShareholderBuy3,125,000$1.60$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Synthetic Biologics (NYSEMKT:SYN)
Latest Headlines for Synthetic Biologics (NYSEMKT:SYN)
Source:
DateHeadline
americanbankingnews.com logoSynthetic Biologics Inc (SYN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 18 at 4:52 AM
americanbankingnews.com logoSynthetic Biologics Inc (SYN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 10 at 11:22 AM
americanbankingnews.com logoSynthetic Biologics Inc (SYN) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - October 10 at 11:22 AM
americanbankingnews.com logoSynthetic Biologics Inc (SYN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 23 at 3:04 AM
americanbankingnews.com logoSynthetic Biologics Inc (SYN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - September 23 at 3:04 AM
finance.yahoo.com logoSynthetic Biologics (SYN) in Focus: Stock Moves 7.7% Higher
finance.yahoo.com - September 19 at 8:16 AM
bizjournals.com logoRockville biotech raises $12 million from tech billionaire Michael Dell
www.bizjournals.com - September 14 at 10:55 AM
seekingalpha.com logoSynthetic Biologics (SYN) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 10:55 AM
finance.yahoo.com logoSynthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
finance.yahoo.com - September 12 at 10:36 AM
finance.yahoo.com logoSynthetic Biologics, Inc. Provides Company Overview and Update on Clinical Development in New SNNLive Video Interview with StockNewsNow.com
finance.yahoo.com - September 6 at 8:56 AM
finance.yahoo.com logoSynthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
finance.yahoo.com - August 29 at 8:23 AM
americanbankingnews.com logoSynthetic Biologics Inc (SYN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - August 29 at 2:56 AM
bizjournals.com logoDaily Technical Summary Reports on Biotech Stocks -- Axovant Sciences, Ampio Pharma, ImmunoCellular Therapeutics, and Synthetic Biologics
www.bizjournals.com - August 9 at 7:59 AM
prnewswire.com logoDaily Technical Summary Reports on Biotech Stocks -- Axovant Sciences, Ampio Pharma, ImmunoCellular ... - PR Newswire (press release)
www.prnewswire.com - August 9 at 7:59 AM
americanbankingnews.com logoSynthetic Biologics Inc (SYN) Issues Earnings Results
www.americanbankingnews.com - August 5 at 7:16 AM
americanbankingnews.com logoSynthetic Biologics Inc (NYSEMKT:SYN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 4 at 4:54 PM
americanbankingnews.com logoSynthetic Biologics Inc (SYN) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 4 at 2:44 PM
prnewswire.com logoSynthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results - PR Newswire (press release)
www.prnewswire.com - August 4 at 8:47 AM
finance.yahoo.com logoSynthetic Biologics reports 2Q loss
finance.yahoo.com - August 4 at 8:47 AM
finance.yahoo.com logoEdited Transcript of SYN earnings conference call or presentation 3-Aug-17 12:30pm GMT
finance.yahoo.com - August 4 at 8:47 AM
finance.yahoo.com logoSynthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results
finance.yahoo.com - August 3 at 7:44 AM
finance.yahoo.com logoSynthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results
finance.yahoo.com - August 3 at 7:44 AM
prnewswire.com logoSynthetic Biologics to Report Second Quarter 2017 Operational Highlights and Financial Results on August 3, 2017 - PR Newswire (press release)
www.prnewswire.com - July 27 at 8:06 AM
finance.yahoo.com logoSynthetic Biologics to Report Second Quarter 2017 Operational Highlights and Financial Results on August 3, 2017
finance.yahoo.com - July 27 at 8:06 AM
americanbankingnews.com logoSynthetic Biologics Inc (NYSEMKT:SYN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 10 at 4:53 PM
americanbankingnews.com logoSynthetic Biologics Inc (SYN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 4:52 PM
reuters.com logoBRIEF-Synthetic Biologics announces allowance of U.S. Patent covering Syn-010
www.reuters.com - June 27 at 8:12 PM
prnewswire.com logoSynthetic Biologics Announces Allowance of Key US Patent Covering SYN-010 Intended for the Novel Treatment of ... - PR Newswire (press release)
www.prnewswire.com - June 27 at 8:51 AM
bizjournals.com logoDigital-to-Biological Converter for On-Demand Production of Biologics Developed by Synthetic Genomics, Inc.
www.bizjournals.com - May 29 at 11:50 AM
streetinsider.com logoSynthetic Biologics (SYN) Announces FDA Breakthrough Therapy Designation for SYN-004 for Prevention of Clostridium Difficile Infection
www.streetinsider.com - May 11 at 10:46 PM
bizjournals.com logoThis Rockville company just won breakthrough status for a drug to prevent hospital infection
www.bizjournals.com - May 11 at 10:46 PM
prnewswire.com logoSynthetic Biologics to Report First Quarter 2017 Operational Highlights and Financial Results on May 4, 2017 - PR Newswire (press release)
www.prnewswire.com - April 26 at 9:35 PM
prnewswire.com logoSynthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal ... - PR Newswire (press release)
www.prnewswire.com - April 21 at 1:13 AM
reuters.com logoBRIEF-Synthetic Biologics reports preclinical data on SYN-005
www.reuters.com - April 19 at 8:58 AM
bizjournals.com logoSynthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
www.bizjournals.com - April 19 at 8:58 AM
biz.yahoo.com logoSYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
us.rd.yahoo.com - March 2 at 8:13 PM
prnewswire.com logoSynthetic Biologics to Report 2016 Year End Operational Highlights ... - PR Newswire (press release)
www.prnewswire.com - February 22 at 10:11 AM
reuters.com logoBRIEF-Synthetic Biologics says confirms key features of Phase 2B/3 trial of SYN-010
www.reuters.com - January 19 at 2:45 AM
us.rd.yahoo.com logoSynthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA
us.rd.yahoo.com - January 19 at 2:45 AM
streetinsider.com logoForm SC 13G/A Synthetic Biologics, Filed by: SABBY ... - StreetInsider.com
www.streetinsider.com - January 12 at 11:39 PM
investopedia.com logoSynthetic Biologics C. Difficile Drug Trial Succeeds
www.investopedia.com - January 7 at 5:43 AM
reuters.com logoSynthetic Biologics' C. difficile mid-stage study meets main goal - Reuters
www.reuters.com - January 6 at 5:53 AM
biz.yahoo.com logoSYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 5:53 AM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Arrowhead Pharma, Intra-Cellular Therapies, Synthetic Biologics, and CoLucid Pharma
www.bizjournals.com - January 3 at 9:24 AM
prnewswire.com logoSynthetic Biologics to Present at the Biotech Showcase™ 2017 Conference - PR Newswire (press release)
www.prnewswire.com - January 3 at 9:24 AM

Social

Chart

Synthetic Biologics (SYN) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.